Elicio Therapeutics, Inc.2025财年第一财季实现净利润-11.21百万美元，同比增加5.24%

市场透视2025-05-19

5月19日，Elicio Therapeutics, Inc.（ELTX.US）公布财报，公告显示公司2025财年第一财季净利润为-11.21百万美元，同比增加5.24%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Elicio Therapeutics, Inc.（ELTX.US）总负债19.24百万美元，其中短期债务926000.00美元，资产负债比为1.47，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536594459?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536594459","market":"us","top_or_hot":-1,"title":"Elicio Therapeutics, Inc.2025财年第一财季实现净利润-11.21百万美元，同比增加5.24%","media":"市场透视","content":"<div>\n<p>5月19日，Elicio Therapeutics, Inc.（ELTX.US）公布财报，公告显示公司2025财年第一财季净利润为-11.21百万美元，同比增加5.24%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Elicio Therapeutics, Inc.（ELTX.US）总负债19.24百万美元，其中短期债务926000.00美元，资产负债比为1.47，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000614a482f18b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elicio Therapeutics, Inc.2025财年第一财季实现净利润-11.21百万美元，同比增加5.24%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElicio Therapeutics, Inc.2025财年第一财季实现净利润-11.21百万美元，同比增加5.24%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000614a482f18b&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Elicio Therapeutics, Inc.（ELTX.US）公布财报，公告显示公司2025财年第一财季净利润为-11.21百万美元，同比增加5.24%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Elicio Therapeutics, Inc.（ELTX.US）总负债19.24百万美元，其中短期债务926000.00美元，资产负债比为1.47，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000614a482f18b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELTX","symbol_name":"Elicio Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000614a482f18b&s=b","article_id":"2536594459","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000614a482f18b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536594459","pubTimestamp":1747584099,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Elicio Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-11.21百万美元，同比增加5.24%；其中营业收入为0.00美元，每股基本收益为-0.87美元。机构评级：截至2025年5月19日，当前有2家机构对Elicio Therapeutics, Inc.目标价做出预测，其中目标均价为11.00美元，其中最低目标价为10.00美元，最高目标价为12.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ELTX":"Elicio Therapeutics","LENZ":"Therapeutics"},"translate_title":"Elicio Therapeutics, Inc. achieved net profits of-US $11.21 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 5.24%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"ELTX":1},"content_text":"5月19日，Elicio Therapeutics, Inc.（ELTX.US）公布财报，公告显示公司2025财年第一财季净利润为-11.21百万美元，同比增加5.24%；其中营业收入为0.00美元，每股基本收益为-0.87美元。从资产负债表来看，Elicio Therapeutics, Inc.（ELTX.US）总负债19.24百万美元，其中短期债务926000.00美元，资产负债比为1.47，流动比率为1.84。机构评级：截至2025年5月19日，当前有2家机构对Elicio Therapeutics, Inc.目标价做出预测，其中目标均价为11.00美元，其中最低目标价为10.00美元，最高目标价为12.00美元。公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。 其专有的 Amphiphile（AMP）平台将研究中的免疫治疗药物直接输送到免疫系统的大脑中心和淋巴结。 其重点是针对经过生物学验证但难以药物治疗的靶点开发癌症免疫疗法.（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536594459","isCrawlerRequest":true}